<DOC>
	<DOCNO>NCT00035529</DOCNO>
	<brief_summary>The purpose study determine whether BMS-188667 decrease multiple sclerosis disease activity MRI examination , well decrease rate clinical MS exacerbation , compare placebo</brief_summary>
	<brief_title>A Study Evaluate Preliminary Efficacy Pharmacokinetics Immunogenicity BMS-188667 Administered Subjects With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Inclusion relapsingremitting MS least 1 exacerbation precede 2 year least 1 MRI lesion stable 2 month prior dose Exclusion progressive MS currently treat immunomodulatory therapy previously treat approved MS drug treatment discontinue lack efficacy active bacterial viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>MS</keyword>
</DOC>